“With the FDA’s recent acceptance of our response to the CRL, our team is energized as we work toward the potential approval of CARDAMYST in its first indication, PSVT,” said Joe Oliveto, President and Chief Executive Officer of Milestone. “In parallel to our regulatory progress, we completed an equity financing in July with high-quality investors which strengthened our balance sheet and extended our operating runway. Our goal is to make CARDAMYST quickly available to PSVT patients, should the FDA grant approval this year.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress
- Milestone Pharmaceuticals Announces Public Offering for $48.7M
- Why Is Milestone Pharmaceuticals Stock (MIST) Down 30% Today?
- Milestone prices $52.5M common shares offering at $1.50 per share
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!